What Is Retatrutide? The Triple Agonist Peptide Researchers Can't Stop Talking About

Retatrutide is a 39-amino acid triple agonist targeting GIP, GLP-1, and glucagon receptors. Learn about its structure, published research, and what makes it unique.

Retatrutide (LY3437943) is a 39-amino acid investigational peptide developed by Eli Lilly that acts as a triple agonist, simultaneously activating GIP, GLP-1, and glucagon receptors. It's the first compound of its kind to target all three metabolic pathways in a single molecule. It hasn't been approved by the FDA and remains under active clinical investigation across multiple Phase 3 trials.

⚗️ FOR RESEARCH USE ONLY. All information on this page is for educational and research purposes. This compound is not approved for human use. Nothing in this article constitutes medical advice, administration guidance, or therapeutic recommendation.

Retatrutide at a Glance

What Is Retatrutide?

Retatrutide is a synthetic peptide. Thirty-nine amino acids built on a GIP (glucose-dependent insulinotropic polypeptide) backbone, engineered to bind three distinct metabolic receptors at once. That's where the "triple agonist" label comes from, and it's what separates this compound from everything else researchers have been working with.

Here's the thing. Most peptides in this class target one receptor. Some target two. Retatrutide goes after three. GIP, GLP-1, and glucagon. All at the same time. In the world of receptor pharmacology, that's a genuinely unusual approach to studying metabolic pathway interactions.

Eli Lilly developed the compound (internal designation LY3437943) and it's been the subject of published research since the early 2020s. The molecule itself is relatively large at approximately 4,731 g/mol, and it's supplied as a lyophilized powder for stability during storage and transport.

Why does the triple mechanism matter to researchers? Because studying how three receptor pathways interact simultaneously opens up questions that single or dual agonist compounds simply can't answer. It's new territory.

How Retatrutide Works at the Molecular Level

Let's break this down receptor by receptor. Not because it's simple (it's not), but because understanding the individual pathways helps explain why triple activation is such an active area of preclinical investigation.

Published Research on Retatrutide

The published literature on retatrutide has grown significantly since Eli Lilly began its clinical investigation program. Here's what's been reported in peer-reviewed journals and conference presentations.

Phase 2 Trial Data

A 2023 study published in The New England Journal of Medicine (Jastreboff et al.) reported results from a Phase 2 trial involving 338 participants. The study observed body weight reductions of up to 24.2% at 48 weeks at the highest investigated amount. That number caught the attention of researchers across the field because it exceeded what had been reported for dual agonist compounds in comparable study designs.

The 338-participant sample size and 48-week duration made this one of the more substantial published datasets for a triple agonist compound. The results were presented at the American Diabetes Association Scientific Sessions and generated considerable discussion in the research community.

Phase 3 TRIUMPH-4 Results

In December 2025, Eli Lilly released topline results from the TRIUMPH-4 Phase 3 trial. The data showed body weight reductions of up to 28.7%, with an average loss of up to 71.2 lbs at 68 weeks in a study population with knee osteoarthritis.

These numbers represent the highest reported body weight reduction percentages published for any single investigational compound in this class. Worth noting for researchers: this was a specific study population, not a general sample.

Active Phase 3 Program

Retatrutide currently has active Phase 3 clinical trials investigating it across multiple research areas: obesity, type 2 diabetes, MASLD (metabolic dysfunction-associated steatotic liver disease), sleep apnea, chronic low back pain, and cardiovascular and renal outcomes.

The breadth of that trial program tells you something about how the research community views the compound's potential as a multi-pathway research tool. Very few investigational peptides are being studied across that many areas simultaneously.

Triple vs. Dual vs. Single: The Comparative Research Question

One of the most actively discussed questions in published metabolic receptor research is how triple agonism compares to dual agonism (like tirzepatide, which targets GIP and GLP-1) and single agonism (like semaglutide, which targets GLP-1 alone).

Laboratory receptor binding studies have shown that each approach creates distinct activation patterns. The addition of glucagon receptor engagement appears to produce different downstream signaling cascades in preclinical models. This is still an evolving area of investigation, and researchers note that in vitro findings don't automatically predict the full picture.

What Researchers Should Know About Retatrutide

For laboratory work with retatrutide, quality and handling matter. Here's what the published literature and standard research protocols indicate about proper handling.

Purity Standards

Research-grade retatrutide should have a purity of ≥98%, verified by independent third-party analysis. At WhyNot Labs, every batch is tested by Vanguard Laboratory. Full Certificates of Analysis (COAs) are published for every batch, linked to the specific batch number.

Why does independent testing matter? Because the research peptide market has a transparency problem. Some suppliers test "representative samples" once a quarter. Others don't test at all. Reliable research results require verified compounds — that's pretty basic, but it's worth saying.

Storage and Handling

Retatrutide is supplied as a lyophilized (freeze-dried) powder, which is the standard form for peptide stability during storage and shipping.

Improper storage can degrade the compound and compromise purity, which affects the reliability of research data. Repeated freeze-thaw cycles after reconstitution should be avoided as they accelerate degradation.

Verifying What You've Got

The reality of the research compound market: not every supplier sells what they say they're selling. Independent COAs aren't optional for reliable research outcomes. When evaluating any supplier, look for identity verification, purity analysis, and quantity verification on every batch — not just cherry-picked ones.

Frequently Asked Questions

Research Disclaimer

All products sold by WhyNot Labs are intended for laboratory research use only. Not for human or animal consumption. These products are not drugs, foods, or cosmetics and have not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm you are a qualified researcher over 21 years of age. WhyNot Labs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act.

Written by Ash, Founder of WhyNot Labs. All WhyNot Labs products are independently tested by Vanguard Laboratory with full Certificates of Analysis published for every batch.